When you are represented by someone of Dr Kurtzberg profile . I can only say “ the party has started”
Dr. Kurtzberg conducts both clinical and laboratory-based translational research efforts, all involving various aspects of normal and malignant hematopoiesis. In the laboratory, her early work focused on studies determining the mechanisms that regulate the choice between the various pathways of differentiation available to the pluripotent hematopoietic stem cell.
Her laboratory established a CD7+ cell line, DU.528, capable of multilineage differentiation as well as self-renewal, and subsequently described the aggressive leukemic syndrome of CD7+ALL and demonstrated that a normal counterpart of the CD7+, TN malignant cell can be isolated from postnatal human thymus, bone marrow, umbilical cord blood and G-CSF mobilized peripheral blood progenitor cells.
The leukemic CD7+ cell has been established in model systems nude and SCID mice where direct IL2-cytotoxicity has been demonstrated. The mechanism of IL2-induced cytotoxicity is currently a major focus of work in the laboratory.
One focus of Dr. Kurtzberg's translational research is the use of novel deoxynucleosides to purge normal and malignant T-cells from human bone marrow.
She has also played an important role in the development of PEG-L Asparaginase and Nelarabine, two novel antileukemia drugs that are now used routinely in the clinic. Dr. Kurtzberg is active in the Children's Oncology Group and coordinated the ALinC 16 high risk study for children with newly diagnosed B-lineage acute lymphoblastic leukemia (ALL) as well as relapsed studies for children with T- and B-lineage ALL. Under Dr. Kurtzberg's leadership, Duke has established an internationally known children's transplant program which currently treats children with cancer, blood disorders, immune deficiencies, hemoglobinopathies and inherited metabolic diseases.
Over the past 2 years, the cord blood transplant program at Duke has initiated studies of autologous cord blood in children with neonatal brain injury and cerebral palsy.
Dr. Kurtzberg’s laboratory is also pursuing preclinical studies isolating oligodendrocytes from cord blood with the goal of using these cells for cell therapy to treat acquired agenetic brain injuries in the next few years.
Over the past 2 decades, Dr. Kurtzberg pioneered and is investigating the use of banked umbilical cord blood as an alternative stem cell source for unrelated marrow transplantation. She was awarded with a banking and transplant center contract from NHLBI for 1996-2005, to establish the Carolinas Cord Blood Bank (CCBB)at Duke and was the PI on the cord blood transplantation study (COBLT) in children with hematological malignancies and inborn errors of metabolism. In 2006, the CCBB was awarded a contract from HRSA to become a member bank of the National Cord Blood Inventory (NCBI) of the CW Bill Young Cell Transplantation Program after legislation was passed in 2005 to establish this network. Dr. Kurtzberg is also the Duke PI for the NIH-sponsored, Blood and Marrow Transplant Clinical Trials Network (BMT-CTN) and the PI on a national trial comparing single and double cord blood transplantation in children with hematological malignancies. In 2008-2009, Dr. Kurtzberg’s lab pioneered studies to predict cord blood potency through novel assays on segments attached to cryopreserved cord blood units. The program is also performing translational research testing cord blood expansion, cellular targeted therapies and tissue repair and regeneration.Education and TrainingM.D., New York University, 1976Selected Grants and AwardsDuke Women's Reproductive Health Research ScholarsBlood and Marrow Transplant Clinical Trials NetworkMarcus Foundation Phase II MSC ASDHigh Fidelity Diffusion MRI for Children with Cerebral Palsy in Stem Cell TherapyMarcus Foundation Grant AgreementReprogramming Inflammatory Cells with Mesenchymal Stromal Cell RNA GranulesData Enabled Automation for the Improved Efficiency, Yield, and Reproducibility of the Manufacturing of Human Umbilical Cord Tissue Mesenchymal Stromal Cells for Clinical Therapeutic UseRVT 802: FDA BLA Support (Addendum #23)Transfusion Medicine and Hematology(TEACH) Immune Tolerance NetworkHypoxic Ischemic Encephalopathy-Phase II-Robertson FoundationNMDP / Be the Match BiobankTransmission electron microscope (TEM)UNC - Duke Immunotherapy Training ProgramClinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (CTRL-ALT-D) BMT CTN Protocol #1702RVT 802: Research Thymus Manufacturing (Addend #19)Optimized Procedures and SOP's for Thymus Tissue ProcessingComparing Reduced Intensity Allo HCT to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Intermediate-2 and High Risk Myelodysplastic SyndromeReduced-Intensity Conditioning for Children and Adults with Hemophagocytic Syndromes orReduced-Intensity Conditioning for Children and Adults with Hemophagocytic Syndromes or Selected Primary Immune Deficiencies (RICHI)Tissue Collection and Processing for Thymus TransplantationNotch Mediated Expansion of Cord Blood Progenitors for Stem Cell Transplant2018 Cord Blood Collection AgreementRVT 802: Media Fill and FDA Response (Addend #20)Enzyvant Sub Award Vendors (Addend #18)NMDP / Be the Match BiobankHRSA National Cord Blood Inventory, Fifth CohortRVT 802: Media Fill and FDA Response (Addend #17)HRSA National Cord Blood InventoryCreation of Storage Space Dedicated to RVT-802 (Project Addendum #15)Purchase of Environmental Monitoring (EM) Equipment (Project Addendum #14)Raw Materials Testing (Project Addendum #16)Potency and Release Assays for Thymus Tissue ProcessingDuke-UNC Clinical Hematology and Transfusion Research Career Development ProgramA Phase I Trial of a Single ProHema CB Product (Ex Vivo Modulated Human Cord Blood Cells) as Part of Single Cord Blood Unit Transplant after Busulfan/Cyclophosphamide/ATG Conditioning for Pediatric Patients with Inherited Metabolic DisordersA Single-arm, Prospective Study of Remestemcel-L, Ex-Vivo Cultured Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Patients who have Failed to Respond to Steroid Treatment for Acute GVHDSafety Follow-up Through 180 Days of Treatment with Remestemcel-L in Study MSB-GVHD001 in Pediatric Patients who have Failed to Respond to Steroid Treatment for Acute GVHDDuke Research Training Program for Pediatricians(TEACH) Atemtuzumab, Costimulation Blockade and Sirolimus: A Tolerogenic Canvas for Donor Antigen Delivery via MesenchymalNMDP New or Expanded Collection Hospital Development for Public Cord Blood CollectionNational Marrow Donor Program Kit Collection Project Agreement 210224Notch Mediated Expansion of Cord Blood Progenitors for Stem Cell TransplantAutologous Umbilical Cord Blood Infusion for Children with Autism Spectrum Disorder, ASDCorrelating TCR Diversity to Immune Reconstitution After Cord Blood TransplantNMDP New or Expanded Collection Hospital Development for Public Cord Blood CollectionResearch Training In Neuro-OncologyCord Blood Biomarkers for EngraftmentUNC-Duke Collaborative Clinical Pharmacology Postdoctoral Training ProgramNational Marrow Donor Program Amendment 1 to the Duke University Cord Blood Collection Agreement 206432HRSA National Cord Blood Inventory, Fifth CohortClinical Oncology Research Career Development ProgramMultidisciplinary Neonatal Training GrantNational Marrow Donor Program ISBT 128 Implementation Project Agreement 205793Maintenance of NHLBI Cord Blood UnitsNew or Expanded Collection Hospital Development for Public Cord Blood CollectionNutrition, Deregulation of Imprinted Genes and Rapid Weight Gain in Early LifeHRSA National Cord Blood Inventory, Fifth CohortCTSA ULResearch Training In Neuro-OncologyNon-Myeloablative Cord Blood TransplantationIn-utero Exposure and Infant Loss of IGF2 ImprintingParental Caregiving of Children PostStem Cell TransplantTransplant Centers For Clinical Research OnCollection And Storage Centers For Clinical Research...Pediatric Oncology Group (POG)Pediatric Oncology GroupPediatric Oncology Group StudiesPediatric Oncology Group StudiesViral Control And Immune Reconstitution In Hiv InfectionViral Control & Immune Reconstitution In Hiv InfectionCancer Center Core Support GrantComprehensive Cancer Center Core Support GrantAutologous Bone Marrow Transplantation In Breast And OvariAutologous Bone Marrow Transplantation-Breast And OvarianPediatric Oncology Group StudiesPediatric Oncology Group StudiesEffect Of Swainsonine On Human Bone Marrow Stem Cells TreaEffect Of Swainsonine On Human Bone Marrow Stem Cells TreaPublicationsKurtzberg, Joanne. “The view for cord blood is "cup half full" not "cup half empty".” Stem Cells Transl Med, July 3, 2020. https://doi.org/10.1002/sctm.20-0260.
Expand
(20min delay)